Published on 24/12/2025
Strategic Approaches to Site Selection in China’s Expanding Clinical Research Network
Introduction
China has rapidly emerged as one of the largest clinical research hubs in the world, supported by regulatory reforms, increased site accreditation, and government investment in medical infrastructure. As the National Medical Products Administration (NMPA) expands the number of accredited clinical trial sites, sponsors face both opportunities and challenges in designing effective site selection strategies. The choice between Tier-1 hospitals in metropolitan areas and Tier-2 hospitals in regional centers directly affects recruitment, data quality, and trial timelines. This article explores best practices for site selection in China’s expanding research network, addressing regulatory frameworks, operational considerations, and case examples.
Background and Regulatory Framework
NMPA Site Accreditation System
Historically, only a limited number of hospitals were authorized to conduct clinical trials in China. In 2019, reforms shifted the system from site-by-site approval to a filing-based accreditation system. Now, hospitals that meet GCP standards can register with the NMPA and conduct trials across multiple therapeutic areas, expanding the national research network.
Ethics Committee Oversight
Each accredited site must maintain a functioning ethics committee with trained members and standardized operating procedures. The NMPA reviews ethics committee capacity during site inspections
Case Example: Expansion of Tier-2 Sites
A multinational sponsor expanded a cardiovascular trial from Tier-1 hospitals in Shanghai to Tier-2 hospitals in Jiangsu Province. With targeted training and CRO support, the sponsor improved recruitment diversity and achieved enrollment targets ahead of schedule.
Core Clinical Trial Insights
Tier-1 vs. Tier-2 Hospital Considerations
Tier-1 hospitals offer advanced infrastructure, experienced investigators, and strong QA systems, but face heavy competition for patient recruitment. Tier-2 hospitals provide access to new patient populations but may require additional training and monitoring to ensure compliance.
Feasibility Assessments
Effective site selection requires thorough feasibility assessments, including evaluation of investigator experience, staff training, patient pool size, and prior trial performance. Sponsors should also assess data quality systems and ethics committee efficiency.
Geographic and Demographic Diversity
Recruiting patients across multiple regions improves representativeness of Chinese data for global submissions. Sponsors should include both urban and rural hospitals to capture variations in patient demographics and disease prevalence.
CRO Role in Site Selection
CROs support sponsors by conducting site assessments, coordinating training, and ensuring compliance with NMPA requirements. Local CRO expertise is particularly valuable in evaluating Tier-2 hospitals and navigating regional differences.
Operational Challenges
Challenges in site selection include variable infrastructure quality, inconsistent training standards, and administrative delays in ethics committee approvals. Sponsors must plan for additional monitoring and resource allocation at less experienced sites.
Data Quality and Inspection Readiness
NMPA inspections emphasize data integrity and source documentation. Sponsors must ensure that all selected sites maintain complete trial master files (TMFs), validated electronic systems, and SOP-driven workflows to pass inspections.
Best Practices & Preventive Measures
Sponsors should:
– Balance site selection between Tier-1 and Tier-2 hospitals.
– Conduct robust feasibility and patient pool assessments.
– Verify site accreditation and ethics committee capacity.
– Provide additional training and monitoring for less experienced sites.
– Partner with CROs for site evaluation and operational support.
– Audit site compliance during initiation to ensure readiness.
These best practices reduce risks and enhance trial efficiency.
Scientific & Regulatory Evidence
The NMPA’s site accreditation reforms align with ICH E6(R2) GCP and WHO guidelines on site quality. Evidence shows that diverse recruitment across accredited hospitals strengthens the generalizability of Chinese data and accelerates global approvals.
Special Considerations
Rare disease and pediatric trials require specialized sites with unique expertise and infrastructure. Sponsors must carefully evaluate site capacity and patient access in these therapeutic areas, often partnering with academic hospitals or national centers of excellence.
When Sponsors Should Seek Regulatory Advice
Sponsors should seek NMPA advice when planning multicenter trials involving untested or newly accredited hospitals. Regulatory consultations help clarify expectations for monitoring, ethics committee oversight, and data integrity requirements.
Case Studies
Case Study 1: Oncology Trial Expansion
A sponsor added Tier-2 hospitals to an oncology MRCT to expand patient access. With CRO training and enhanced monitoring, data from these sites were accepted by FDA, EMA, and NMPA, demonstrating the viability of diversified site strategies.
Case Study 2: Cardiovascular Trial Site Selection
A cardiovascular sponsor compared enrollment rates across Tier-1 and Tier-2 hospitals. While Tier-1 hospitals achieved higher-quality data, Tier-2 hospitals provided faster recruitment, highlighting the value of mixed site strategies in balancing quality and timelines.
FAQs
1. What are Tier-1 and Tier-2 hospitals in China?
Tier-1 hospitals are large metropolitan centers with advanced infrastructure and experienced staff. Tier-2 hospitals are regional centers with growing trial capacity but require additional support.
2. How does NMPA accredit clinical trial sites?
Sites file for accreditation by demonstrating compliance with GCP standards. Once approved, they can conduct trials across multiple therapeutic areas.
3. What challenges exist in Tier-2 hospitals?
Challenges include limited infrastructure, less experience in GCP, and slower ethics committee approvals, requiring extra CRO and sponsor support.
4. How do sponsors assess site feasibility?
Through evaluation of investigator qualifications, patient pool size, data quality systems, ethics committee capacity, and prior trial performance.
5. Can data from Tier-2 hospitals be used in global submissions?
Yes, if compliance with GCP is demonstrated and data integrity is maintained. Sponsors must provide additional oversight to ensure quality.
6. What role do CROs play in site selection?
CROs provide local expertise in site evaluation, training, monitoring, and regulatory compliance, supporting sponsors in selecting high-performing sites.
Conclusion & Call-to-Action
China’s expanding clinical research network offers sponsors access to a broader range of sites and patient populations. Strategic site selection—balancing Tier-1 expertise with Tier-2 diversity—strengthens recruitment, data quality, and global acceptance. Sponsors should adopt evidence-based site strategies, partner with CROs, and engage regulators proactively to maximize the benefits of China’s expanding research infrastructure.